Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors
Ilan Gruenwald, Boaz Appel, Noam D. Kitrey and Yoram Vadri
A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Extracorporeal Shock Wave Therapy for the Treatment of Peyronie’s Disease
A. Palmieri, C. Imbimbo, N. Longo, F. Fusco, P. Verze, F. Mangiapia, and V. Mirone
Can Low-Intensity Extracorporeal Shockwave Therapy Improve Erectile Function? A 6-Month Follow-Up Pilot Study in Patients with Organic Erectile Dysfunction
Yoram Vardi, Boaz Appel, Giris Jacob, Omar Massarwi, and Ilan Gruenwald
Tadalafil Once Daily and Extracorporeal Shock Wave Therapy in the Management of Patients with Peyronie’s Disease and Erectile Dysfunction: Results From a Prospective Randomized Trial
A. Palmieri, C. Imbibmo, M. Creta, P. Verze, F. Fusco, and V. Mirone
Low-Intensity Extracorporeal Shock Wave Therapy – A Novel Effective Treatment for Erectile Dysfunction in Severe ED Patients Who Respond Poorly to PDE5 Inhibitor Therapy
Intensity Extracorporeal Shock Wave Therapy Have a Physiological Effect on Erectile Function? Short-Term Results of a Randomized, Double-Blind, Sham Controlled Study
Yoram Vardi, Boaz Appel, Amichai Kilchevsky and Ilan Gruenwald
Evaluation of Clinical Efficacy, Safety and Patient Satisfaction Rate After Low-Intensity Extracorporeal Shockwave Therapy for the Treatment of Male Erectile Dysfunction: an Australian First Open-Label Single-Arm Prospective Clinical Trial